Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Icatibant (Firazyr) vs Vasopressin (Vasostrict)
An educational, source-based comparison of Icatibant (Firazyr) and Vasopressin (Vasostrict) — how each peptide works, what it's researched for, and what to know before going deeper.
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
- Hereditary angioedema (acute attacks)
- • FDA-approved.
- • Injection-site reactions very common.
Endogenous nonapeptide that activates V1 vascular receptors to cause vasoconstriction and V2 renal receptors for water reabsorption. Used to raise blood pressure in catecholamine-resistant shock.
- Septic shock
- Cardiac arrest (historical)
- Diabetes insipidus
- • FDA-approved.
- • Ischemic complications possible at high doses.
Icatibant (Firazyr) vs Vasopressin (Vasostrict) — Key differences
- Class: Icatibant (Firazyr) is classified as Bradykinin Antagonist · Immunology, while Vasopressin (Vasostrict) is Vasopressor · Hormonal.
- Primary research focus: Icatibant (Firazyr) — hereditary angioedema (acute attacks); Vasopressin (Vasostrict) — septic shock.
- Tag: FDA-Approved · Rare Disease vs FDA-Approved · Critical Care.